Accelerate Diagnostics, Inc. announced a private placement of 3,954,546 series A convertible preferred stock at an par value of $0.001, issue price of $7.7 per shares for gross proceeds of $30,450,004.2 on September 22, 2021.The company will issue securities pursuant to exemption provided under Regulation D. The company issued the funding in multiple tranches of 2,636,364 Series A Preferred Shares were issued and sold to the Schuler Parties for aggregate proceeds of approximately $20.3 million. The second tranche for the remaining 1,318,182 Series A Preferred Shares for aggregate proceeds of approximately $10.2 million is expected to close on October 31, 2021 or such other date as the parties may agree. The securities are issued under pursuant to Section 4(a)(2) of the Securities Act (as defined below) and Rule 506 promulgated thereunder.